Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device

Inclusion Criteria: * Adult men and women subjects, aged 18 years old and over at screening visit * Subjects with neuropathology that the principal investigator considers including in this study. * Survival expectancy greater than 72 hours * Subject or legal authorized representative (per local regulation) is able and willing to comply with the requirements of the protocol * Subject or legal authorized representative (per local regulation) is able to understand and sign written informed consent to participate in the study Exclusion Criteria: * Local ear infection * Known allergy or hypersensitivity to any of the test materials or contraindication to test materials * For women of childbearing potential: pregnancy (positive pregnancy test) or breast-feeding * Subjects currently enrolled in or less than 30 days post-participation in other investigational device or drug study(s), or receiving other investigational agent(s) * Any condition that may jeopardize study participation (e.g., abnormal clinical or laboratory finding) or interpretation of study results, or may impede the ability to obtain informed consent (e.g., mental condition)